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IMPACT OF TREATMENT OF OCULAR CHRONIC GVHD WITH A SCLERAL
LENS PROSTHETIC DEVICE AS A NATIONAL NETWORK OF CLINICAL CEN-
TERS EXPANDS
Jacobs, D.S.1,2, Le, H.-G.T.1, Carrasquillo, K.G.1 1Boston Foundation for
Sight, Needham, MA; 2Harvard Medical School, Boston, MA
Purpose: To study impact of Prosthetic Replacement of the Ocular
Surface Ecosystem (PROSE) treatment in patients with ocular
chronic graft-versus-host-disease (cGVHD) as clinical services ex-
pand to partner clinics based at academic tertiary eye care centers
across the United States (US).
Methods: Retrospective review of PROSE manufacturing database
from Jan 2002 through March 2011. Number of patients treated for
diagnosis of ocular cGVHD by year, gender, age, baseline NEI
VFQ-25, state of residence, and location of treatment are reported.
Baseline Composite NEI VFQ-25 score and self-reported general
health score, and changes in those scores at 6 months, in a 4-month
2010 cohort of patients frommain center and two partner clinics, are
compared by t-test.
Results: 333 patients with ocular cGVHD were treated with scleral
lens prosthetic devices from 2002 through March 2011. M:F 5
187:146. Mean age at time of treatment is 50 years613. One patient
with ocular cGVHD was treated in 2002, increasing to 78 patients
with this diagnosis treated in 2010. Percentage of patients treated
at partner clinics increased from 16% in 2009, to 33% in 2010, to
64% in the first quarter of 2011. Significant improvement in visual
function was observed in patients treated at main center in Massa-
chusetts (mean improvement 5 30pts, n 5 18 p\0.001) and in pa-
tients treated at partner clinics (mean improvement 5 41pts, n 5
6, p\0.001). There is no significant difference in baseline scores, al-
though there is trend to lower scores at partner clinics for Composite
NEI VFQ-25score, p 5 0.051.
Conclusions:There is increased utilization of PROSE treatment for
ocular cGVHD over the past decade in the US, particularly with the
establishment of partner clinics. Limited data indicates that patients
treated at partner clinics have same or lower baseline visual function
and self-reported general health status when compared to patients
treated at main center. Patients treated at partner clinics achieve sim-
ilar high level of positive impact on visual function as patients treated
at main center.443
ORAL LOADING OF TACROLIMUS AND SUB-THERAPEUTIC LEVELS ON
THE DAY OF TRANSPLANT DO NOT PREDICT THE INCIDENCE OF ACUTE
GRAFT VERSUS HOST DISEASE OR SURVIVAL AFTER ALLOGENEIC STEM
CELL TRANSPLANT
MacPherson, J.1, Bachier, C.1, LeMaistre, C.F.1, Sowell, H.2, Garcia, L.2,
Curel-Sanchez, A.2, Cain, W.2, Caga, U.2, Means, J.2, Shaughnessy, P.1
1Texas Transplant Institute, San Antonio, TX; 2Methodist Hospital,
Texas Transplant Institute, San Antonio, TX
Tacrolimus is proven to be effective in the prophylaxis of acute
graft versus host disease (aGVHD) after allogeneic stem cell trans-
plant (ASCT). Published studies that initiate tacrolimus loading in-
travenously indicate that levels should be between 5 and 20ug/L on
the day of transplant (Day 0). Our institution often performs ASCT
in the outpatient setting and therefore developed a process for oral
loading of tacrolimus. We retrospectively reviewed our experience
in 94 consecutive patients (pts) who received ASCT from 10/10
HLA matched donors; 47 were matched sibling donors (MSD) and
47 were matched unrelated donors (MUD) with a median age of
50 and 52 respectively. Preparative regimens were IV busulfan based
in 68 patients (BuFlu n5 44, BuCy n5 24), TBI based in 19 pts and
other in 7 pts. All patients received GVHD prophylaxis with tacro-
limus started orally between day -3 and -1 at a dose of 0.06mg/kg/
day divided twice daily. Standard short course methotrexate
(MTX) was prescribed for all pts (D1 dose 5 15mg/m2, D3, D6
and D11 dose5 10mg/m2). Pts who had sub-therapeutic tacrolimus
levels (less than 5ug/L on day 0 were compared to patients who had
therapeutic tacrolimus levels (greater than 5ug/L) for any incidence
of aGVHD and overall survival (OS). Sixty-nine patients had tacro-
limus levels less than 5ug/L on day 0 and 25 pts had tacrolimus levelsof 5ug/L or greater. There was no difference in the incidence of
aGVHD or survival between the groups (Table 1). Thirty-one pts
did not receive the entireMTXdose prescribed (most commonly be-
cause of withholding day 11MTX dose), but there was no significant
difference in the incidence of aGVHD in these pts despite the level of
tacrolimus on day 0. With a median follow up of 441 days, 54/94 pts
(57%) are alive; 40/69 pts (58%) had day 0 tacrolimus levels less than
5ug/L and 14/25 pts (56%) had day 0 levels greater than or equal to
5ug/L. In conclusion, oral loading of tacrolimus prior to ASCT at
our institution results in sub-therapeutic levels on the day of trans-
plant in the majority of pts; however, this does not appear to impact
incidence of aGVHDor survival. This study was limited by its retro-
spective nature, small size and single center experience. Prospective
randomized studies will be needed to determine if oral loading of ta-
crolimus impacts outcomes of ASCT.
Tacro < 5ug/L Tacro $ 5ug/L Overall
Outcome (n 5 69) (n 5 25) (n 5 94) p valueMUD OS 26.7 22.3 25.4 0.266
SIB OS 22.1 18.8 22.9 0.451
Overall OS 24.8 23.4 24.4 0.781
MUD aGVHD 19/31 (61%) 13/16 (50%) 32/47 (68%) 0.345
SIB aGVHD 15/38 (39%) 5/9 (56%) 20/47 (43%) 0.584
Overall aGVHD 34/69 (49%) 18/25 (72%) 52/94 (55%) 0.117Tacro indicates tacrolimus; OS, overall survival; MUD, matched unre-
lated donor; SIB, sibling. Survival determined in mean months from
date of transplant.444
RISK FACTORS FOR THE DEVELOPMENT OF GRAFT VERSUS HOST DIS-
EASE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANPLANTATION
(allo-HSCT)
Hamilton, B.K.1, Bolwell, B.J.1, Rybicki, L.2, Kalaycio, M.1, Tench, S.1,
Hanna, R.3, Duong, H.1, Sobecks, R.1, Pohlman, B.1, Andresen, S.1,
Copelan, E.A.1 1Cleveland Clinic Taussig Cancer Institute, Cleveland,
OH; 2Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; 3Cleve-
land Clinic, Cleveland, OH
Graft versus host disease (GVHD) remains a major cause of mor-
bidity and mortality in allo-HSCT. In this study, we evaluated the
correlation of acute and chronic GVHD with patient characteristics
and specific GVHD prevention regimens.
We identified 628 patients who underwent allo-HSCT from
2000-2010 at our single institution. Diagnoses included AML,
MDS, CML,MF andMPN, ALL, lymphoma and AA.We evaluated
all transplant and donor types including myeloablative (MA), re-
duced intensity (RIC); matched related donors (MRD), unrelated
donors (URD), and umbilical cord blood donors (UCB). GVHD
prophylaxis regimens included the use of methotrexate (MTX)
with tacrolimus (FK) or cyclosporine (CSA); and mycophenolate
mofetil (MMF) with FK or CSA. Stepwise Cox proportional hazards
analysis was used to identify multivariable risk factors for develop-
ment of aGVHD, cGVHD and relapse.
In multivariable analysis, three variables were identified that were
associated with an increased risk of aGVHD: transplant type, donor
type, and cell source.MA regimen vs RIC (HR 1.99, 95%CI 1.4-2.8,
p\0.001), URD transplant recipients vs MRD (HR 1.2, 95% CI
1.01-1.5, p 5 0.048), and transplant from peripheral stem cells
(PSC) vs bone marrow (BM) or UCB (HR 1.61, 95% CI 1.18-
2.19, p 5 0.002) were associated with increased risk for aGVHD.
Older age was associated with decreased risk of grade 3-4 aGVHD,
(HR 0.84, 95%CI 0.73-0.98, p5 0.024), perhaps owing to the use of
RIC regimens in older pts. There were no other statistically signifi-
cant correlations. Female gender was associated with higher risk (HR
1.3, 95% CI 1.04-1.7, p 5 0.022) of cGVHD. CSA/MTX prophy-
laxis compared to FK/MTX demonstrated an increased risk of
cGVHD, (HR 1.84, 95% CI 1.24-2.74, p 5 0.002). There was no
significant association between relapsed disease in regards to trans-
plant type, donor type, or GVHD prevention regimens. However,
PSC had an increased risk of disease relapse (HR 2.38, 95% CI
